Okyo Pharma LTD OKYO
We take great care to ensure that the data presented and summarized in this overview for OKYO Pharma Ltd is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OKYO
Top Purchases
Top Sells
About OKYO
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Insider Transactions at OKYO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 27
2023
|
Gabriele M Cerrone Executive Chairman |
BUY
Other acquisition or disposition
|
Indirect |
70,071
+0.76%
|
$70,071
$1.5 P/Share
|
|
Oct 23
2023
|
Gabriele M Cerrone Executive Chairman |
BUY
Other acquisition or disposition
|
Indirect |
499,468
+5.2%
|
$499,468
$1.5 P/Share
|
|
Sep 15
2023
|
John P Brancaccio Director |
BUY
Open market or private purchase
|
Direct |
16,670
+50.0%
|
$16,670
$1.5 P/Share
|
|
May 19
2022
|
Gabriele M Cerrone Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
5,800,000
+1.05%
|
$0
$0.08 P/Share
|
|
May 19
2022
|
Gabriele M Cerrone Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
37,500
+37.5%
|
$150,000
$4.0 P/Share
|
|
May 19
2022
|
Gary S Jacob Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+50.0%
|
$50,000
$4.0 P/Share
|
|
May 17
2022
|
Gabriele M Cerrone Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
1,625,000
+0.3%
|
$0
$0.06 P/Share
|